Full-Time

Scientist I/Scientist II

Medicinal Chemistry

Confirmed live in the last 24 hours

Hexagon Bio

Hexagon Bio

51-200 employees

Biotechnology firm developing medicines using genomics

Data & Analytics
Biotechnology
Healthcare

Compensation Overview

$120k - $160kAnnually

+ Bonus + Equity

Entry

Menlo Park, CA, USA

Ability to work at Menlo Park, CA laboratories.

Category
Bioinformatics
Computational Biology
Genomics
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Scientist I: Ph.D. degree in organic or medicinal chemistry
  • Scientist II: Ph.D. degree in organic or medicinal chemistry and 2 years postdoctoral or industry experience
  • Ability to perform complex multistep synthesis quickly, efficiently, and safely
  • Ability to work at Menlo Park, CA laboratories
Responsibilities
  • Design of new drug candidates
  • Multistep synthesis of new drug candidates
  • May manage aspects of a drug discovery project
  • May manage chemistry at a contract research organization

Hexagon Bio focuses on discovering and developing new medicines through synthetic biology and data science. By utilizing reduced DNA sequencing costs, the company accesses extensive genomic data from various species. Their proprietary algorithm identifies small molecule inhibitors that target specific proteins involved in diseases like cancer. Hexagon Bio's synthetic biology platform enables rapid production of lead compounds for clinical development, allowing for quicker advancement compared to traditional methods. The team consists of experts in various scientific fields, collaborating to enhance medical discovery. Targeting the pharmaceutical and healthcare sectors, Hexagon Bio aims to develop treatments for complex diseases and generates revenue through licensing drug candidates to larger companies for further development. Their goal is to leverage genomic data and synthetic biology to create effective new medicines.

Company Stage

Late Stage VC

Total Funding

$178.6M

Headquarters

Menlo Park, California

Founded

2016

Growth & Insights
Headcount

6 month growth

-11%

1 year growth

-20%

2 year growth

27%
Simplify Jobs

Simplify's Take

What believers are saying

  • Hexagon Bio's recent $77.3 million Series B financing and $61 million funding round highlight strong investor confidence and provide substantial capital for advancing their discovery platform.
  • The company's innovative approach to drug discovery using microbial genomes positions it at the cutting edge of biotechnology, offering significant potential for breakthroughs in treating complex diseases.
  • A specialized team of experts in computational biology, biochemistry, chemistry, and software engineering enhances Hexagon Bio's capability to push the boundaries of medical discovery.

What critics are saying

  • The reliance on licensing deals for revenue means Hexagon Bio's financial stability is tied to the success of its partnerships with larger pharmaceutical companies.
  • The competitive landscape in biotechnology and drug discovery is intense, requiring continuous innovation to maintain a leading position.

What makes Hexagon Bio unique

  • Hexagon Bio leverages synthetic biology and data science to mine microbial genomes for small molecule inhibitors, setting it apart from traditional drug discovery methods.
  • Their proprietary algorithm allows for rapid identification and development of lead compounds, significantly reducing the time to clinical development compared to conventional approaches.
  • The company's focus on licensing early-stage drug candidates to larger pharmaceutical companies provides a unique revenue model that mitigates the risks associated with late-stage drug development.

Help us improve and share your feedback! Did you find this helpful?